PMID- 27710978
OWN - NLM
STAT- MEDLINE
DCOM- 20170313
LR  - 20220409
IS  - 2296-5262 (Electronic)
IS  - 2296-5270 (Linking)
VI  - 39
IP  - 10
DP  - 2016
TI  - Efficacy and Long-Term Safety of Everolimus in Pancreatic Neuroendocrine Tumor 
      Associated with Multiple Endocrine Neoplasia Type I: Case Report.
PG  - 643-645
AB  - BACKGROUND: Approximately 10% of pancreatic neuroendocrine tumors (NET) are 
      associated with familial syndromes, with the most common type being multiple 
      endocrine neoplasia type 1 (MEN-1). However, the available evidence on how to 
      treat NET comes from studies in sporadic NET. CASE REPORT: Here we report the 
      case of a 51-year-old male patient with a metastatic MEN-1-associated pancreatic 
      NET and hypercalcemia related to primary hyperparathyroidism and tumor-secreted 
      parathyroid-related protein. The patient was treated with everolimus, and showed 
      complete resolution of hypercalcemia and tumor control for 3 years when he 
      presented with pulmonary cryptococcosis and disease progression. CONCLUSION: This 
      case report describes the activity of everolimus in a patient with 
      MEN-1-associated pancreatic NET, its efficacy in treating malignant hypercalcemia 
      associated with NET and the risk of opportunistic infections with prolonged use 
      of this agent.
CI  - (c) 2016 S. Karger GmbH, Freiburg.
FAU - Maia, Manuel C D F
AU  - Maia MC
AD  - Department of Clinical Oncology, Instituto de Ensino e Pesquisa Sao Lucas, Sao 
      Paulo, Brazil.
FAU - Muniz Lourenco, Delmar Jr
AU  - Muniz Lourenco D Jr
FAU - Riechelmann, Rachel
AU  - Riechelmann R
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20160912
PL  - Switzerland
TA  - Oncol Res Treat
JT  - Oncology research and treatment
JID - 101627692
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/adverse effects
MH  - Everolimus/*administration & dosage/*adverse effects
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia/*drug therapy/pathology
MH  - Neuroendocrine Tumors/*drug therapy/pathology
MH  - Opportunistic Infections/*chemically induced/pathology/prevention & control
MH  - Pancreatic Neoplasms/*drug therapy/pathology
MH  - Treatment Outcome
EDAT- 2016/10/07 06:00
MHDA- 2017/03/14 06:00
CRDT- 2016/10/07 06:00
PHST- 2016/03/02 00:00 [received]
PHST- 2016/06/20 00:00 [accepted]
PHST- 2016/10/07 06:00 [entrez]
PHST- 2016/10/07 06:00 [pubmed]
PHST- 2017/03/14 06:00 [medline]
AID - 000448699 [pii]
AID - 10.1159/000448699 [doi]
PST - ppublish
SO  - Oncol Res Treat. 2016;39(10):643-645. doi: 10.1159/000448699. Epub 2016 Sep 12.